TEL AVIV, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter of 2014 and will host a corporate update conference call on Thursday, May 15, 2014.
Conference Call & Webcast | |
Thursday, May 15, 2014 @ 8:30am Eastern Time/5:30am Pacific Time | |
Domestic: | 855-469-0611 |
International: | 484-756-4341 |
Passcode: | 43962198 |
Webcast: | www.alcobra-pharma.com |
Replays | |
Domestic: | 855-859-2056 |
International: | 404-537-3406 |
Passcode: | 43962198 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.